ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
Total Operating Expenses: $23.8 million in Q3 2024. SG&A Expenses: $19.3 million, expected to increase in Q4 2024. GAAP Net Loss: $19.1 million or $0.20 per share in Q3 2024. Cash, Cash Equivalents, and Short-term Investments: $204.6 million at the end of Q3 2024. Pro Forma Cash Position: $349.6 million including $145 million upfront payment from ALK. Warning! GuruFocus has detected 3 Warning Sign with SPRY. Release Date: November 13, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript ARS Pharmaceuticals Inc ( NASDAQ:SPRY ) received approval for NEPHI 2 mg in both the United States and Europe, marking it as the first needle-free epinephrine product for allergic reactions. The company has launched NEPHI in the U.S., with strong support and enthusiasm from patients, caregivers, and the medical community. A strategic licensing agreement with AOK has been established, expanding NEPHI's reach to Europe, Canada, and
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United StatesGlobeNewswire
- ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 11/13/24 - Miss
SPRY
Sec Filings
- 11/14/24 - Form 4
- 11/14/24 - Form 4
- 11/13/24 - Form 4
- SPRY's page on the SEC website